App-Quantinova.ai

Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma: Updated Interim Analysis of a Prospective, Multicentre, Observational Study

Massimo Offidani - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Multiple Myeloma

Velaglucerase alfa

Evidence Supporting Light Chain Cast Nephropathy As a Myeloma Defining Event

Andrea Angioi - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Renal disease

N/A

Carfilzomib and Lenalidomide for the Treatment of Primary Plasma Cell Leukemia: Final Results of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged ≥66 Years

Pellegrino Musto - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Primary plasma cell leukemia

Dexamethasone

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years

Niels W.C.J. van de Donk - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Primary plasma cell leukemia

Dexamethasone

Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study

Meletios A. Dimopoulos - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Hyaluronidase

MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Elena Zamagni - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Cytokine release syndrome

Lenalidomide

Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study

Iryna Dekhtiarenko - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Uliprisnil acetate

Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone Study

Maria-Victoria Mateos - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

daratumumab Intravenous

Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19)

Meral Beksac - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Cyclophosphamide

Dedalo: Phase II Study of Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Patients with Relapsed/Refractory Multiple Myeloma and 17p Deletion

Vittorio Montefusco - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

Novel Tissue-Specific Targeted Radiation Delivery Reduces GI Injury and T Cell Trafficking Attenuating Allogeneic Immune Attack to Reduce GvHD in a Murine BMT Model

Srideshikan Sargur Madabushi - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Graft-versus-host disease

N/A

Overexpression of CXCR4 Enhances the Efficacy of CAR-T Therapy for Acute Myeloid Leukemia

Marta Biondi - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Plerixafor

ATP-Dependent Induction of IDO1 Expression in Dendritic Cells Is Controlled through Non-Canonical NF-Kb Signaling Via P2Y11R and Leads to T Regulatory Cells Induction

Darina Ocadlikova - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

BAY117082

CAR.CD123-NK Cells Have an Equally Effective but Safer Off-Tumor/on-Target Profile As Compared to CARCD123-T Cells for the Treatment of Acute Myeloid Leukaemia

Simona Caruso - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

GM-CSF

Overcoming CD19-Negative Relapses in Patients with B-Cell Lymphomas Treated with Tisagenlecleucel

Guido Ghilardi - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B lymphoblastic leukemia

tisagenlecleucel-t

Tuned IL3-Zetakine Coupled to a CD33 Costimulatory Receptor As a Dual CAR for Safer and Selective Targeting of Acute Myeloid Leukemia

Vincenzo Maria Perriello - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

N/A

Preclinical Development of a CAR-T Cell Approach Targeting the CD84 Antigen Associated to Pediatric Acute Myeloid Leukemia

Martina Pigazzi - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hematological malignancies

IL-15

Final Results of Phase I/II Study of Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed Post-HSCT

Federico Lussana - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B-cell acute lymphoblastic leukemia

Cyclophosphamide

Reprogramming Macrophages Using Autologous Hematopoietic Stem Cells As Immunotherapy for Glioblastoma: TEM-GBM Study (NCT03866109)

Francesca Farina - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

lenograstim

Lava-051, a Novel Bispecific Gamma-Delta T-Cell Engager (Gammabody), in Relapsed/Refractory MM and CLL: Pharmacodynamic and Early Clinical Data

Arnon P. Kater - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

Filters

30348 Abstracts